.
A brand-new antiviral drug that might end up being the first oral medicine for the novel coronavirus is presently being tested, as Atea Pharmaceuticals has announced a deal with Swiss giant Roche for development and circulation.
The drug is called AT-527 and it’s currently in Stage 2 screening, with the final stage of clinical trials set for the first half of2021
This new medication is expected to obstruct the replication of the coronavirus inside the cell and prevent its ability to spread in the body.
The U.S. Food and Drug Administration (FDA) officially authorized Gilead Sciences’ Veklury (remdesivir) as the very first treatment for COVID-19 on Thursday. The drug showed in scientific trials that it could help patients recover faster than standard care. The drug is administered intravenously, and it’s not the kind of treatment that can be used in a house setting.
Scientists are currently working on what may turn out to be the first oral antiviral drug for COVID-19 that might be used at home. The announcement came from Atea Pharmaceuticals on the very same day the FDA issued the final remdesivir approval.
Atea developed a compound called AT-527 which is presently in Phase 2 screening. The business explained in a news release that Roche paid $350 million in money upfront, with further turning point payments and royalties to follow. Under the terms of the agreement, Atea would offer and disperse the drug in America, with Roche dealing with the international market.
” This cooperation with Roche enhances Atea’s efforts and underscores the capacity for AT-527 to effectively deal with the COVID-19 crisis on a worldwide scale,” Atea CEO and founder Jean-Pierre Sommadossi stated in a declaration. “AT-527 is expected to be ideally suited to combat COVID-19 as it prevents viral replication by disrupting viral RNA polymerase, an essential component in the replication equipment of RNA viruses. Notably, the manufacturing procedure for our small particle direct-acting antiviral permits us to produce AT-527 quickly and at scale.”.
Not much is known about AT-527 for the time being, aside from Atea’s discuss the matter. Essentially, the drug should prevent the infection from reproducing when it contaminates cells. Here’s how the biopharmaceutical business describes the drug:.
AT-527 is an orally administered, direct-acting antiviral agent stemmed from Atea’s purine nucleotide prodrug platform. AT-527 is presently under examination as a treatment for patients with COVID-19 AT-527 is desi
Read More